ID

15705

Beskrivning

Risperidone vs. Olanzapine as add-on Treatment in Treatment Resistant Depression; ODM derived from: https://clinicaltrials.gov/show/NCT01282632

Länk

https://clinicaltrials.gov/show/NCT01282632

Nyckelord

Versioner (1)
  1. 2016-06-08 2016-06-08 -
Uppladdad den

8 juni 2016

DOI

För en begäran logga in.

Licens

Creative Commons BY 4.0
Modellkommentarer :

Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.

Tillbaka till modellkommentarer
Itemgroup-kommentar för :

Item-kommentar för :

Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.

Eligibility Subjects Had Unipolar, Non-psychotic Major Depression NCT01282632

Engelsk

Eligibility Subjects Had Unipolar, Non-psychotic Major Depression NCT01282632

1 Formulär  
Inclusion Criteria
Beskrivning

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. male or female out-patients;
Beskrivning

subjects who meet all of the following criteria are eligible for this trial:

Datatyp

boolean

Alias
UMLS CUI [1]
C0079399
2. aged between 18 and 65 years (extremes included);
Beskrivning

age

Datatyp

boolean

Alias
UMLS CUI [1]
C0001779
3. subjects suffering from a current episode of non-psychotic, unipolar depression as determined by the depression section of the scid-iv.
Beskrivning

unipolar depression

Datatyp

boolean

Alias
UMLS CUI [1]
C0041696
4. subjects with treatment resistant depression defined as failure to respond to two successive courses of monotherapy given in adequate doses for a minimum of 4 weeks with different antidepressants (the current course of antidepressant can be considered to second failed course) and;
Beskrivning

two successive courses with different antidepressants

Datatyp

boolean

Alias
UMLS CUI [1]
C2063866
5. subjects currently taking a ssri or a snri for at least 4 weeks, at adequate dosage and not responding, as defined by a score of 3 or more on the cgi-i. and no dose change for 2 weeks prior to entry.
Beskrivning

taking a ssri or a snri

Datatyp

boolean

Alias
UMLS CUI [1]
C0360105
UMLS CUI [2]
C1579361
6. a minimum score of 16 on the 17 item ham-d
Beskrivning

ham-d score

Datatyp

boolean

Alias
UMLS CUI [1]
C0451203
7. ability to provide informed consent.
Beskrivning

informed consent

Datatyp

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Beskrivning

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. subjects who are actively suicidal as determined by a score of 3 on the suicide item on the ham-d or in the opinion of the treating physician;
Beskrivning

subjects meeting one or more of the following criteria cannot be selected:

Datatyp

boolean

Alias
UMLS CUI [1]
C0438696
2. other current (active symptomatology within the last 2 months) axis i dsm iv diagnosis other than nicotine or caffeine dependence or other than an anxiety disorder.
Beskrivning

other mental disorder

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0004936
UMLS CUI [1,2]
C0205394
3. use of disallowed concomitant therapy; or other psychotropic medication except occasional benzodiazepines. (see "rescue medication");
Beskrivning

disallowed concomitant therapy

Datatyp

boolean

Alias
UMLS CUI [1]
C1707479
4. history of alcohol or drug abuse or dependence, within 3 months of entry into the trial);
Beskrivning

alcohol or drug abuse

Datatyp

boolean

Alias
UMLS CUI [1]
C0038586
5. seizure disorder requiring medication;
Beskrivning

seizure disorder

Datatyp

boolean

Alias
UMLS CUI [1]
C0014544
6. active medical condition that requires urgent attention or that would contra-indicate the use of risperidone or olanzapine. for example stable thyroid disease or asthma would be acceptable, whereas acute hepatitis would not;
Beskrivning

active medical condition that requires urgent attention

Datatyp

boolean

Alias
UMLS CUI [1]
C0009488
7. participation in an investigational drug trial within 30 days prior to the start of the trial
Beskrivning

participation in an investigational drug trial

Datatyp

boolean

Alias
UMLS CUI [1]
C2348568
8. known sensitivity to risperidone, olanzapine or the antidepressant;
Beskrivning

sensitivity to risperidone olanzapine or the antidepressant

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0073393
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C0171023
UMLS CUI [3,1]
C0020517
UMLS CUI [3,2]
C0003289
9. history of neuroleptic malignant syndrome (nms);
Beskrivning

neuroleptic malignant syndrome

Datatyp

boolean

Alias
UMLS CUI [1]
C0027849
10. subjects who are at imminent risk of injury to self or others, or causing significant damage to property, as judged by the investigator;
Beskrivning

imminent risk of injury to self or others

Datatyp

boolean

Alias
UMLS CUI [1]
C0419435
11. female subjects who are pregnant or breast-feeding;
Beskrivning

pregnancy or breast-feeding

Datatyp

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
12. female subject of childbearing potential without adequate contraception (sterilization, barrier, iud, oral contraceptives, intramuscular or subdermal administration of depot-progestagens);
Beskrivning

adequate contraception

Datatyp

boolean

Alias
UMLS CUI [1]
C0700589
15. previous exposure to risperidone or olanzapine during the current episode.
Beskrivning

exposure to risperidone or olanzapine

Datatyp

boolean

Alias
UMLS CUI [1]
C0073393
UMLS CUI [2]
C0171023
Tillbaka till toppen

Similar models

Eligibility Subjects Had Unipolar, Non-psychotic Major Depression NCT01282632

1 Formulär
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Item Group
C1512693 (UMLS CUI)
gender
Item
1. male or female out-patients;
boolean
C0079399 (UMLS CUI [1])
age
Item
2. aged between 18 and 65 years (extremes included);
boolean
C0001779 (UMLS CUI [1])
unipolar depression
Item
3. subjects suffering from a current episode of non-psychotic, unipolar depression as determined by the depression section of the scid-iv.
boolean
C0041696 (UMLS CUI [1])
two successive courses with different antidepressants
Item
4. subjects with treatment resistant depression defined as failure to respond to two successive courses of monotherapy given in adequate doses for a minimum of 4 weeks with different antidepressants (the current course of antidepressant can be considered to second failed course) and;
boolean
C2063866 (UMLS CUI [1])
taking a ssri or a snri
Item
5. subjects currently taking a ssri or a snri for at least 4 weeks, at adequate dosage and not responding, as defined by a score of 3 or more on the cgi-i. and no dose change for 2 weeks prior to entry.
boolean
C0360105 (UMLS CUI [1])
C1579361 (UMLS CUI [2])
ham-d score
Item
6. a minimum score of 16 on the 17 item ham-d
boolean
C0451203 (UMLS CUI [1])
informed consent
Item
7. ability to provide informed consent.
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
actively suicidal
Item
1. subjects who are actively suicidal as determined by a score of 3 on the suicide item on the ham-d or in the opinion of the treating physician;
boolean
C0438696 (UMLS CUI [1])
other mental disorder
Item
2. other current (active symptomatology within the last 2 months) axis i dsm iv diagnosis other than nicotine or caffeine dependence or other than an anxiety disorder.
boolean
C0004936 (UMLS CUI [1,1])
C0205394 (UMLS CUI [1,2])
disallowed concomitant therapy
Item
3. use of disallowed concomitant therapy; or other psychotropic medication except occasional benzodiazepines. (see "rescue medication");
boolean
C1707479 (UMLS CUI [1])
alcohol or drug abuse
Item
4. history of alcohol or drug abuse or dependence, within 3 months of entry into the trial);
boolean
C0038586 (UMLS CUI [1])
seizure disorder
Item
5. seizure disorder requiring medication;
boolean
C0014544 (UMLS CUI [1])
active medical condition that requires urgent attention
Item
6. active medical condition that requires urgent attention or that would contra-indicate the use of risperidone or olanzapine. for example stable thyroid disease or asthma would be acceptable, whereas acute hepatitis would not;
boolean
C0009488 (UMLS CUI [1])
participation in an investigational drug trial
Item
7. participation in an investigational drug trial within 30 days prior to the start of the trial
boolean
C2348568 (UMLS CUI [1])
sensitivity to risperidone olanzapine or the antidepressant
Item
8. known sensitivity to risperidone, olanzapine or the antidepressant;
boolean
C0020517 (UMLS CUI [1,1])
C0073393 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0171023 (UMLS CUI [2,2])
C0020517 (UMLS CUI [3,1])
C0003289 (UMLS CUI [3,2])
neuroleptic malignant syndrome
Item
9. history of neuroleptic malignant syndrome (nms);
boolean
C0027849 (UMLS CUI [1])
imminent risk of injury to self or others
Item
10. subjects who are at imminent risk of injury to self or others, or causing significant damage to property, as judged by the investigator;
boolean
C0419435 (UMLS CUI [1])
pregnancy or breast-feeding
Item
11. female subjects who are pregnant or breast-feeding;
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
adequate contraception
Item
12. female subject of childbearing potential without adequate contraception (sterilization, barrier, iud, oral contraceptives, intramuscular or subdermal administration of depot-progestagens);
boolean
C0700589 (UMLS CUI [1])
exposure to risperidone or olanzapine
Item
15. previous exposure to risperidone or olanzapine during the current episode.
boolean
C0073393 (UMLS CUI [1])
C0171023 (UMLS CUI [2])
Tillbaka till toppen 

Kontakt

Använd detta formulär för feedback, frågor och förslag på förbättringar.

Fält markerade med * är obligatoriska.

Hjälp

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial